Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
E Tsourdi, MC Zillikens, C Meier, JJ Body… - The Journal of …, 2021 - academic.oup.com
Context Denosumab discontinuation is characterized by an increase in bone turnover
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral …
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral …
Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2‐year randomized study
AS Sølling, T Harsløf, B Langdahl - Journal of Bone and Mineral …, 2020 - academic.oup.com
Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We
investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density …
investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density …
Hypoxia-inducible factors regulate osteoclasts in health and disease
X Meng, B Wielockx, M Rauner… - Frontiers in Cell and …, 2021 - frontiersin.org
Hypoxia-inducible factors (HIFs) have become key transcriptional regulators of metabolism,
angiogenesis, erythropoiesis, proliferation, inflammation and metastases. HIFs are tightly …
angiogenesis, erythropoiesis, proliferation, inflammation and metastases. HIFs are tightly …
[PDF][PDF] Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
B Langdahl - 2020 - scholar.archive.org
Context: Denosumab discontinuation is characterized by an increase in bone turnover
overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral …
overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral …